Replies to post #2348 on Universal Detection Technology (fka UNDT)

[BpL]

I got in about 2 months ago at .0031, only bought $353 worth of shares. So I don't have a lot invested in; I went away on vacation last week and I wasn't really able to track the progress of it. Of course that's the one week it shoots sky high! Needless to say I was happy it went up, but not too pleased I couldn't sell at its high-water mark.

I liked the news about the patent; I don't know why the PPS is trickling down to where I bought it. You're right about people panicking... this stock seems to be a good one and people shouldn't panic and sell at the bid. If they wanna take profits, sure. But go ahead and sell at the ask, don't panic and wait. The sell will get filled and the PPS won't suffer.

[powertogetwealth]

Check out the news today:

Beacon Equity Issues Trading Outlook for Universal Detection Technology
Beacon Equity Issues Trading Outlook for Universal Detection Technology
DALLAS, Aug. 3, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring bioterrorism detection devices maker Universal Detection Technology (OTCBB:UNDT). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Universal Detection Technology (OTCBB:UNDT) should be of particular interest to other scientific manufacturing companies: Cepheid (Nasdaq:CPHD), Northrup Grumman Corp. (NYSE:NOC), and Thermo Fisher Scientific Inc. (NYSE:TMO).

It is available at: http://www.beaconequity.com/i/UNDT

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Universal Detection Technology (UNDT) is a developer, manufacturer and marketer engaged in the bioterrorism detection devices market in the United States. It designs automated air monitoring instruments used to detect pollutant and bioterrorism airborne particles. The Company's BSM-2000 is its flagship product used to detect bacterial endospores, such as anthrax, ricin, botulinum toxin, plague and SEBs.

In the report, the analyst notes:

"The Company has licensed a spore detection technology from NASA's Jet Propulsion Laboratory and has developed a unique device capable of detecting abnormal levels of spores in the air in real-time, which can be an indication of a possible anthrax attack.

"Demand for bioterrorism defense products is expected to grow by 6% per year and is expected to reach $13.4 billion by 2010 in the United States, according to Department of Homeland Security (DHS) projections. Through the U.S. Office of Health Affairs (OHA), the National Biosurveillance Integration Center (NBIC) budgeted $2.6 billion to monitor air and water in more than 30 jurisdictions throughout the United States. The bulk of overall market demand, approximately 75%, will come from the Department of Health and Human Services."

To read the entire report visit: http://www.beaconequity.com/i/UNDT

BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
[e-mail]



Source: GlobeNewswire (August 3, 2009 - 6:50 AM EDT)